Background. We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative. Methods. A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and overall survival time (OS) were assessed by Kaplan–Meier analysis. Univariate and multivariate analyses were performed to identify factors that could predict the prognosis of metastatic cervical cancer in the previously described patients. Results. The objective response rate was 25%, whereas the mPFS and mOS were 6.1 and 11.3 months, respectively. The therapeutic efficacy was influenced by the characteristics of TILs, infection with HPV, and development of fever just after the therapy. Conclusion. Overall, our results show that the combination therapy of TILs and anti-PD1 significantly improves the prognosis of metastatic cervical cancer.

中文翻译：

---

TIL 和抗 PD1 疗法：PDL1 阴性转移性宫颈癌的替代联合疗法。

背景。我们研究了 TIL 和抗 PD1 联合治疗对 MSI 低表达和 PDL1 阴性的转移性宫颈癌患者的疗效。方法。共有 80 名患者接受了 TILs 和抗 PD1 联合治疗，通过 Kaplan-Meier 分析评估了无进展生存时间（PFS）和总生存时间（OS）。进行单变量和多变量分析以确定可以预测先前描述的患者中转移性宫颈癌预后的因素。结果. 客观缓解率为 25%，而 mPFS 和 mOS 分别为 6.1 个月和 11.3 个月。治疗效果受 TILs 特征、HPV 感染和治疗后发热的影响。结论。总体而言，我们的研究结果表明，TILs 和抗 PD1 的联合治疗显着改善了转移性宫颈癌的预后。